Skip to main content
. 2022 Jan 27;135(8):901–910. doi: 10.1097/CM9.0000000000001984

Figure 1.

Figure 1

Telomere shortening, DNA mutations, mitochondrial dysfunction, somatic and mitochondrial DNA mutations, epigenetic alterations, impairment of proteostasis, aberrant intracellular communication, immunosenescence, etc., reduce the numbers of somatic cells and SCs under the conditions of limited cell division, disruption of cell homeostasis, and senescence and disease induction. SC therapies represent a new strategy for the treatment of aging-related diseases. SCs: Stem cells.